Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5466]

Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target

Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target

EHA 17: Malignant cells in patients with chronic lymphocytic leukaemia escape T cell recognition and attack

EHA 17: Malignant cells in patients with chronic lymphocytic leukaemia escape T cell recognition and attack

Cancer Research Technology and BioInvent enter oncology collaboration

Cancer Research Technology and BioInvent enter oncology collaboration

Hepatitis C 'switch' offers target for new drug research

Hepatitis C 'switch' offers target for new drug research

Experimental combination for stomach and oesophageal cancer

Experimental combination for stomach and oesophageal cancer

ASCO 2012: New MEK inhibitor, trametinib, improves survival in advanced melanoma

ASCO 2012: New MEK inhibitor, trametinib, improves survival in advanced melanoma

ASCO 2012: Afatinib delays progression of advanced lung adenocarcinomas, particularly in genetic subset of tumours

ASCO 2012: Afatinib delays progression of advanced lung adenocarcinomas, particularly in genetic subset of tumours

ATM and MET kinases are antagonists of p53-dependent apoptosis

ATM and MET kinases are antagonists of p53-dependent apoptosis

ASCO 2012: New treatment for HER2-positive advanced breast cancer, trastuzumab emtansine, improves progression-free survival over current standard

ASCO 2012: New treatment for HER2-positive advanced breast cancer, trastuzumab emtansine, improves progression...

ASCO 2012: Promising activity for new PD-1 targeted immune therapy

ASCO 2012: Promising activity for new PD-1 targeted immune therapy

More from ecancer